Curaleaf just bypassed boardroom doors and went straight to the public. The U.S. cannabis heavyweight announced an unsolicited takeover bid for Edmonton-based Aurora Cannabis, offering a cash-and-stock deal valued at US$4.00 per share. Aurora's leadership isn't rolling out the red carpet. They are pushing back, telling investors to hold tight while a special committee evaluates the offer.
If this deal goes through, it redraws the map of the global cannabis trade.
The Numbers Behind the Bid
Let's look at the math. Curaleaf's proposed structure offers 0.3463 subordinate voting shares plus US$0.75 in cash for every single Aurora share you own. According to Curaleaf CEO Boris Jordan, that represents a 45% premium over Aurora's 30-day volume-weighted average price (VWAP) of US$2.75. Strip out the cash sitting on Aurora's balance sheet, and that premium spikes to a staggering 110%.
The entire transaction values Aurora at roughly $272 million. Curaleaf also slapped a cap price of $5.00 on the consideration in case its own stock shoots up before shares are taken up.
Why is Curaleaf pushing so hard? Simple. International scale.
By absorbing Aurora, Curaleaf secures immediate access to over 50 tons of annual EU-GMP certified cultivation and manufacturing capacity. That includes Aurora's recent pickup of Safari Flower Company. Mix that with Curaleaf's existing processing footprint in Portugal, Spain, and its dominant distribution network across Germany, the UK, and Poland, and you get a massive global player. Combined, the two companies would command trailing twelve-month revenues exceeding US$1.5 billion.
Why Aurora Management Is Dragging Its Feet
Aurora's board claims they aren't completely shutting the door, but they certainly aren't opening it wide either. Analysts at TD Cowen pointed out that the current offer still undervalues Aurora's long-term medical cannabis dominance and balance sheet strength.
Aurora leadership noted that their lead independent director corresponded with Curaleaf as recently as July 24, signaling that they wanted to focus on executing their independent business plan rather than jumping at the first hostile knock. Aurora's board has formed a special committee to review the terms, but their immediate message to shareholders is clear: do nothing right now.
What Happens Next for Investors
Hostile takeovers rarely end with a quiet handshake. Curaleaf took this public because private letters sent on June 23 and July 7 hit a brick wall. Curaleaf claims Aurora refused constructive dialogue. Aurora disputes that narrative entirely.
If you own Aurora shares, you're caught in the middle of a high-stakes corporate game. The formal bid will likely take weeks to wind through regulatory filings with Canadian securities watchdogs and the U.S. Securities and Exchange Commission. Once filed, the clock starts ticking on a mandatory 105-day window unless Curaleaf alters its timeline.
Watch how Aurora's special committee responds to the valuation. If they successfully argue that $4.00 per share leaves money on the table, Curaleaf will have to sweeten the pot or walk away. Sit tight, monitor the filings, and don't panic sell based on headline noise alone.
